• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Maine institute to shut down its centerpiece research

Maine institute to shut down its centerpiece research

July 19, 2011
CenterWatch Staff

What was supposed to have been a major biomedical research center in Maine when it was unveiled in 2005 is shutting down the centerpiece of its program in September due to lack of public and private funding, according to the Bangor Daily News. The Maine Institute for Human Genetics and Health will no longer carry out its primary purpose, which was to explore the links between environmental exposures to arsenic, radon and other toxic materials and cancer.

Dr. Erik Steele, chief medical officer of the institute’s corporate parent Eastern Maine Healthcare Systems, has served as executive director of the MIHGH since last fall. He told the newspaper it would take at least $5 million a year for five years to keep the program alive. A private consultant told Steele the institute is "just too small be competitive."

Increased competition nationwide for government research funding and private industry investment, in combination with the widespread economic downturn and general budget-tightening for hospitals and health care systems, Steele said, have made it necessary to discontinue the ambitious central mission of MIHGH. About 20 people will lose their jobs as a result.

The center was paid for by taxpayer-approved bonds and a $7 million grant from the Department of Defense. When opened in 2005, the institute was to be the cornerstone of a regional biomedical research triangle with Eastern Maine Medical Center, The Jackson Laboratory and the University of Maine as key partners. Unlike conducting bench research or clinical trials alone, MIHGH was to specialize in “translational” studies that bridge the two.

EMHS is committed to maintaining the institute’s Sylvan Road lab and the high-end equipment it houses, Steele said, and other research projects headquartered there will continue. Those projects include studies conducted by research faculty at the University of Maine and Husson University, as well as some projects affiliated with The Jackson Laboratory in Bar Harbor. In addition, MIHGH will continue to offer commercial services for other researchers, including DNA analysis and other “high-end” lab services, Steele said.

UMaine vice president for research Michael Eckardt said two faculty researchers and several graduate students are currently engaged in “very productive” projects at MIHGH and have been assured they will be allowed to finish those projects. Eckardt said EMHS has been forthright about the “somewhat disappointing” changes at MIHGH and is working to help identify alternative research sites for UMaine students. The Graduate School of Biomedical Sciences has to date enrolled between 20 and 30 students, he said.

Steele said MIHGH has accomplished a lot in its brief tenure, including attracting new research and clinical expertise to the area, forging collaborative relationships with other facilities, and achieving national recognition for its work in cancer epidemiology.

Steele said Eastern Maine Healthcare Systems will continue to support clinical trials and other primary care initiatives. "We'll be looking closely at the science of delivering health care to rural populations," he told the Bangor Daily News. "It's closer to what we do every day."

Upcoming Events

  • 17May

    Three Data Trends to Consider Now When Developing Your Decentralized Clinical Trial Strategy

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing